BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 19180517)

  • 1. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
    Young A; Vummidi D; Visovatti S; Homer K; Wilhalme H; White ES; Flaherty K; McLaughlin V; Khanna D
    Arthritis Rheumatol; 2019 Aug; 71(8):1339-1349. PubMed ID: 30762947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
    Mittoo S; Jacob T; Craig A; Bshouty Z
    Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study.
    Bernstein EJ; Peterson ER; Sell JL; D'Ovidio F; Arcasoy SM; Bathon JM; Lederer DJ
    Arthritis Rheumatol; 2015 May; 67(5):1314-22. PubMed ID: 25581250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.
    Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A
    Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
    Trad S; Amoura Z; Beigelman C; Haroche J; Costedoat N; Boutin le TH; Cacoub P; Frances C; Wechsler B; Grenier P; Piette JC
    Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary hypertension complicating connective tissue disease.
    Lynch JP; Belperio JA; Saggar R; Fishbein MC; Saggar R
    Semin Respir Crit Care Med; 2013 Oct; 34(5):581-99. PubMed ID: 24037627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study.
    Pasarikovski CR; Granton JT; Roos AM; Sadeghi S; Kron AT; Thenganatt J; Moric J; Chau C; Johnson SR
    Arthritis Res Ther; 2016 Jan; 18():30. PubMed ID: 26819137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
    Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
    Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
    Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
    J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.